Congress orders study on hair straighteners and cancer risk in women of color

What it does

This bill directs the Secretary of Health and Human Services, working with the FDA and National Institutes of Health, to conduct a two-year study on whether chemical hair straighteners are linked to uterine cancer, with special attention to higher rates among women of color. The study will review existing research, examine whether different product formulations (dyes, bleach, perms) carry different risks, and recommend whether the FDA should require additional safety testing before products reach the market.

Why we flagged it

The bill's sole operative mechanism is a directive to conduct a federally funded study on a potential occupational and consumer health risk, with the explicit goal of informing future FDA safety policy. This is straightforward public health research, not a regulatory change, appropriation, or private benefit.

What the text implies

• Study results may trigger FDA rulemaking requiring manufacturers to conduct additional toxicology, epidemiology, or safety testing before market entry, raising compliance costs for the hair-care industry.
• Disaggregation by product type (dyes, bleach, perms) may reveal that certain formulations carry higher risk, potentially leading to selective bans or restrictions on specific chemical combinations.
• Explicit focus on women of color may highlight disparities in product marketing, usage patterns, or occupational exposure (e.g., among salon workers), potentially informing workplace safety or consumer protection policy beyond the study itself.
• Two-year timeline means results will likely be published in 2027, during a period when FDA leadership and congressional priorities may differ from current conditions, affecting likelihood of regulatory follow-up.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill creates a public health investigation into a potential cancer risk affecting millions of women, particularly women of color who use these products at higher rates. The study may lead to stronger FDA safety requirements, giving consumers better information and potentially preventing harm; there is no direct cost to citizens, only a potential future regulatory requirement on manufacturers.

Named in the bill

Department of Health and Human Services, Food and Drug Administration, National Institutes of Health, House Committee on Energy and Commerce, Senate Committee on Health, Education, Labor, and Pensions, hair straightener manufacturers, women of color

Where it stands

38 cosponsors: 38 Democrats.

• Jul 15, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jul 15, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.